Model OGB21502 -Tetra-Valent Molecule

OGB21502 is an augmented FGF21 on a nonclinical stage that is conjugated to albumin, GLP-1, GCG, and α-cytokine. This tetra-specific, tetra-valent molecule is only 120 kDa in size, demonstrating good physical stability. This well-balanced tetra-agonist may be the ideal therapy for the treatment of fibrosis as well as NASH. OGB21502 is scheduled for IND filing in 2023.